Conference Coverage

AAG Spells Bad News for Some Protease Inhibitors

Published in AIDS Weekly, February 27th, 1995

A glycoprotein contained in normal human serum profoundly decreases the anti-HIV effect of several members of a new class of antiretroviral drugs.

Protease inhibitors are designed to interfere with the function of an enzyme crucial to HIV replication. As currently available antiretroviral agents target a different viral enzyme, it is hoped that combination therapy with both types of drug will deliver a powerful two-pronged attack on HIV. Several protease inhibitors are already in Phase II clinical trials (see the accompanying article).

But data from one of these trials, together with laboratory studies, show that the human serum alpha-1 acid...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1995-02-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry